Programmed Death-Ligand 1 (PD-L1), also known as CD274 or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumor cells resistant to CD8+ T cell-mediated lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumor aggressiveness and risk of death, and, in ovarian cancer, higher expression of this protein has lead to significantly poorer prognosis. PD-L1 has also been linked to systemic lupus erythematosus and cutaneous melanoma. When considered in adjunct with CD8+ tumor-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.
The PD-L1 (IHC411-1) antibody is intended for qualified laboratories to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed, paraffin-embedded tissue sections using IHC test methods.
- application:
- IHC
- Catalog number:
- IHC411-1
- clone:
- IHC411
- concentration:
- N/A
- Datasheet:
- formulation:
- Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide
- immunogen:
- Recombinant Human PD-L1
- isotype:
- IgG
- MSDS:
- N/A
- notes:
- For research use only, not for use in diagnostic procedures.
The datasheet for this product (see above) is intended to serve as an example only. Please refer to the datasheet provided with the antibody for precise details. - Other names:
- N/A
- Protocol:
- N/A
- size:
- 1.0 mL
- storage:
- 2-8°C (Do not freeze).
- Species:
- Human
- Host:
- Mouse